

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview

Query Builder Report: This report details the results of an analysis generated by the Sentinel Query Builder application. Query Builder enables FDA to visualize, draft, and create standardized medical product utilization queries examining dispensing patterns and cohort characteristics using a set of pre-defined parameters. This is a Type 5 (Medical Product Utilization) analysis as described in the Query Request Package (QRP) documentation.

Request Description: In this report, we examined utilization patterns of baloxavir and oseltamivir for prophylaxis and treatment of influenza.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.0.0.

Data Source: We executed this request on March 2, 2023 in the Merative™ MarketScan® Commercial Claims and Encounters Database and Medicare Supplemental Database, which included 157 million members. The study period included data from October 24, 2018 to March 31, 2022. Please see Appendix A for data availability dates.

Limitations: Algorithms used to define exposures and inclusion and exclusion criteria are imperfect; thus it is possible that there may be misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel Query Builder, please refer to the documentation (<https://dev.sentinelssystem.org/projects/QB/repos/querybuilder/browse>).

Table of contents	
Table 1a	Baseline table (Baloxavir)
Table 1b	Baseline table (Baloxavir, excluding influenza)
Table 1c	Baseline table (Baloxavir, including influenza)
Table 1d	Baseline table (Oseltamivir)
Table 1e	Baseline table (Oseltamivir, excluding influenza)
Table 1f	Baseline table (Oseltamivir, including influenza)
Table 2a	Distribution of cumulative exposure duration, by length categories, all episodes, in days
Table 2b	Distribution of cumulative exposure duration, by length categories, all episodes, in days, by sex
Table 2c	Distribution of cumulative exposure duration, by length categories, all episodes, in days, by age group (Years)
Table 3a	Descriptive statistics of cumulative exposure duration, all episodes, in days
Table 3b	Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex
Table 3c	Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (Years)
Table 4a	Distribution of first exposure episode duration, by length categories, in days
Table 4b	Distribution of first exposure episode duration, by length categories, in days, by sex
Table 4c	Distribution of first exposure episode duration, by length categories, in days, by age group (Years)
Table 5a	Descriptive statistics of first exposure episode duration, in days
Table 5b	Descriptive statistics of first exposure episode duration, in days, by sex
Table 5c	Descriptive statistics of first exposure episode duration, in days, by age group (Years)
Table 6a	Distribution of second and subsequent exposure episode duration, by length categories, in days
Table 6b	Distribution of second and subsequent exposure episode duration, by length categories, in days, by sex
Table 6c	Distribution of second and subsequent exposure episode duration, by length categories, in days, by age group (Years)
Table 7a	Descriptive statistics of second and subsequent exposure episode duration, in days
Table 7b	Descriptive statistics of second and subsequent exposure episode duration, in days, by sex
Table 7c	Descriptive statistics of second and subsequent exposure episode duration, in days, by age group (Years)
Table 8a	Distribution of all episode durations, by length categories, in days
Table 8b	Distribution of all episode durations, by length categories, in days, by sex
Table 8c	Distribution of all episode durations, by length categories, in days, by age group (Years)
Table 9a	Descriptive statistics of all episode durations, in days
Table 9b	Descriptive statistics of all episode durations, in days, by sex
Table 9c	Descriptive statistics of all episode durations, in days, by age group (Years)
Table 10a	Distribution of days supplied per dispensing, by length categories
Table 10b	Distribution of days supplied per dispensing, by length categories, by sex
Table 10c	Distribution of days supplied per dispensing, by length categories, by age group (Years)
Table 11a	Descriptive statistics of days supplied per dispensing
Table 11b	Descriptive statistics of days supplied per dispensing, by sex
Table 11c	Descriptive statistics of days supplied per dispensing, by age group (Years)
Table 12a	Descriptive statistics of the length of the first gap between treatment episodes, in days
Table 12b	Descriptive statistics of the length of the first gap between treatment episodes, in days, by sex
Table 12c	Descriptive statistics of the length of the first gap between treatment episodes, in days, by age group (Years)
Table 13a	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days
Table 13b	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by sex
Table 13c	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by age group (Years)
Table 14a	Descriptive statistics of the length of all gaps between treatment episodes, in days
Table 14b	Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex
Table 14c	Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (Years)
Table 15	Counts of reason for censoring, all episodes and first episode
Table 16	Cohort Attrition table
Appendix A	Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2022) as of Query Distribution Date

Table of Contents

Appendix B	Specifications Used to Define Parameters in this Query
Appendix C	List of Generic and Brand Names of Medical Products Used to Define Exposures of Interest in this Request
Appendix D	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request
Appendix E	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Exclusion Criteria in this Request
Appendix F	List of Polymerase Chain Reaction (PCR) Tests Used to Define Inclusion Criteria for this Request
Appendix G	List of Polymerase Chain Reaction (PCR) Tests Used to Define Exclusion Criteria for this Request

Table 1a: Baseline table (Baloxavir)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	33,074	
Demographics		
Mean Age (Years)	36.3	15.9
Age: 00-17 (Years)	6,052	18.3%
Age: 18-24 (Years)	4,529	13.7%
Age: 25-40 (Years)	8,746	26.4%
Age: 41-64 (Years)	13,361	40.4%
Age: 65+ (Years)	386	1.2%
Sex (Female)	17,570	53.1%
Sex (Male)	15,504	46.9%
Year (2018)	309	0.9%
Year (2019)	11,070	33.5%
Year (2020)	16,891	51.1%
Year (2021)	3,293	10.0%
Year (2022)	1,511	4.6%
Recorded history of:		
Prior combined comorbidity score ³	0.3	1.0
Acquired Hypothyroidism	2,522	7.6%
Acute Myocardial Infarction	61	0.2%
Alzheimer's Disease	10	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	33	0.1%
Anemia	1,819	5.5%
Asthma	2,502	7.6%
Atrial Fibrillation	239	0.7%
Benign Prostatic Hyperplasia	546	1.7%
Breast Cancer	275	0.8%
Cataracts	900	2.7%
Chronic Kidney Disease	1,353	4.1%
Chronic Obstructive Pulmonary Disease	1,152	3.5%
Colorectal Cancer	52	0.2%
Depression	3,556	10.8%
Diabetes	2,071	6.3%
Endometrial Cancer	20	0.1%
Glaucoma	673	2.0%
Heart Failure	158	0.5%
Hip / Pelvic Fracture	25	0.1%
Hyperlipidemia	5,920	17.9%
Hypertension	5,959	18.0%
Ischemic Heart Disease	750	2.3%
Lung Cancer	13	0.0%
Osteoporosis	296	0.9%
Prostate Cancer	92	0.3%
Rheumatoid Arthritis / Osteoarthritis	3,039	9.2%
Stroke / Transient Ischemic Attack	175	0.5%

Table 1a: Baseline table (Baloxavir)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	10.2	12.0
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.0	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.7	4.5
Mean number of filled prescriptions	14.4	18.3
Mean number of generics	5.7	5.4
Mean number of unique drug classes	5.3	4.8

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³ The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1b: Baseline table (Baloxavir, excluding influenza)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	11,314	
Demographics		
Mean Age (Years)	38.6	15.8
Age: 00-17(Years)	1,548	13.7%
Age: 18-24 (Years)	1,449	12.8%
Age: 25-40 (Years)	2,977	26.3%
Age: 41-64 (Years)	5,120	45.3%
Age: 65+ (Years)	220	1.9%
Sex (Female)	6,127	54.2%
Sex (Male)	5,187	45.8%
Year (2018)	133	1.2%
Year (2019)	3,575	31.6%
Year (2020)	5,586	49.4%
Year (2021)	1,386	12.3%
Year (2022)	634	5.6%
Recorded history of:		
Prior combined comorbidity score ³	0.4	1.0
Acquired Hypothyroidism	1,018	9.0%
Acute Myocardial Infarction	23	0.2%
Alzheimer's Disease	5	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	20	0.2%
Anemia	714	6.3%
Asthma	827	7.3%
Atrial Fibrillation	101	0.9%
Benign Prostatic Hyperplasia	215	1.9%
Breast Cancer	107	0.9%
Cataracts	371	3.3%
Chronic Kidney Disease	496	4.4%
Chronic Obstructive Pulmonary Disease	407	3.6%
Colorectal Cancer	16	0.1%
Depression	1,271	11.2%
Diabetes	785	6.9%
Endometrial Cancer	6	0.1%
Glaucoma	276	2.4%
Heart Failure	66	0.6%
Hip / Pelvic Fracture	8	0.1%
Hyperlipidemia	2,272	20.1%
Hypertension	2,201	19.5%
Ischemic Heart Disease	314	2.8%
Lung Cancer	10	0.1%
Osteoporosis	146	1.3%
Prostate Cancer	26	0.2%
Rheumatoid Arthritis / Osteoarthritis	1,202	10.6%
Stroke / Transient Ischemic Attack	66	0.6%

Table 1b: Baseline table (Baloxavir, excluding influenza)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	10.7	12.9
Mean number of emergency room encounters (ED)	0.3	0.8
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.0	6.4
Mean number of filled prescriptions	16.3	20.2
Mean number of generics	6.3	5.8
Mean number of unique drug classes	5.8	5.1

¹All metrics based on total number of unique patients
²Value represents standard deviation where no % follows the value
³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).

Table 1c: Baseline table (Baloxavir, including influenza)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	21,914	
Demographics		
Mean Age (Years)	35.1	15.8
Age: 00-17 (Years)	4,537	20.7%
Age: 18-24 (Years)	3,106	14.2%
Age: 25-40 (Years)	5,804	26.5%
Age: 41-64 (Years)	8,300	37.9%
Age: 65+ (Years)	167	0.8%
Sex (Female)	11,528	52.6%
Sex (Male)	10,386	47.4%
Year (2018)	176	0.8%
Year (2019)	7,527	34.3%
Year (2020)	11,363	51.9%
Year (2021)	1,952	8.9%
Year (2022)	896	4.1%
Recorded history of:		
Prior combined comorbidity score ³	0.3	0.9
Acquired Hypothyroidism	1,520	6.9%
Acute Myocardial Infarction	38	0.2%
Alzheimer's Disease	5	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	13	0.1%
Anemia	1,110	5.1%
Asthma	1,688	7.7%
Atrial Fibrillation	139	0.6%
Benign Prostatic Hyperplasia	333	1.5%
Breast Cancer	169	0.8%
Cataracts	534	2.4%
Chronic Kidney Disease	865	3.9%
Chronic Obstructive Pulmonary Disease	747	3.4%
Colorectal Cancer	36	0.2%
Depression	2,305	10.5%
Diabetes	1,297	5.9%
Endometrial Cancer	14	0.1%
Glaucoma	399	1.8%
Heart Failure	93	0.4%
Hip / Pelvic Fracture	17	0.1%
Hyperlipidemia	3,675	16.8%
Hypertension	3,789	17.3%
Ischemic Heart Disease	436	2.0%
Lung Cancer	3	0.0%
Osteoporosis	152	0.7%
Prostate Cancer	66	0.3%
Rheumatoid Arthritis / Osteoarthritis	1,856	8.5%
Stroke / Transient Ischemic Attack	110	0.5%

Table 1c: Baseline table (Baloxavir, including influenza)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	9.9	11.5
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.0	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	3.2
Mean number of filled prescriptions	13.4	17.2
Mean number of generics	5.4	5.2
Mean number of unique drug classes	5.0	4.6

¹All metrics based on total number of unique patients
²Value represents standard deviation where no % follows the value
³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).

Table 1d: Baseline table (Oseltamivir)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	1,111,007	
Demographics		
Mean Age (Years)	30.4	19.7
Age: 00-17 (Years)	401,050	36.1%
Age: 18-24 (Years)	99,680	9.0%
Age: 25-40 (Years)	239,254	21.5%
Age: 41-64 (Years)	348,305	31.4%
Age: 65+ (Years)	22,718	2.0%
Sex (Female)	609,922	54.9%
Sex (Male)	501,085	45.1%
Year (2018)	63,673	5.7%
Year (2019)	581,802	52.4%
Year (2020)	390,000	35.1%
Year (2021)	43,112	3.9%
Year (2022)	32,420	2.9%
Recorded history of:		
Prior combined comorbidity score ³	0.4	1.1
Acquired Hypothyroidism	68,516	6.2%
Acute Myocardial Infarction	2,396	0.2%
Alzheimer's Disease	1,184	0.1%
Alzheimer's Disease, Related Disorders, or Senile Dementia	3,687	0.3%
Anemia	58,312	5.2%
Asthma	100,013	9.0%
Atrial Fibrillation	9,597	0.9%
Benign Prostatic Hyperplasia	14,448	1.3%
Breast Cancer	8,594	0.8%
Cataracts	29,826	2.7%
Chronic Kidney Disease	46,289	4.2%
Chronic Obstructive Pulmonary Disease	38,389	3.5%
Colorectal Cancer	1,684	0.2%
Depression	99,497	9.0%
Diabetes	65,929	5.9%
Endometrial Cancer	738	0.1%
Glaucoma	20,906	1.9%
Heart Failure	7,777	0.7%
Hip / Pelvic Fracture	1,057	0.1%
Hyperlipidemia	167,366	15.1%
Hypertension	166,540	15.0%
Ischemic Heart Disease	23,750	2.1%
Lung Cancer	997	0.1%
Osteoporosis	8,632	0.8%
Prostate Cancer	2,909	0.3%
Rheumatoid Arthritis / Osteoarthritis	82,552	7.4%
Stroke / Transient Ischemic Attack	6,493	0.6%

Table 1d: Baseline table (Oseltamivir)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	9.7	12.6
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.1	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.8	6.9
Mean number of filled prescriptions	12.2	18.0
Mean number of generics	4.8	5.0
Mean number of unique drug classes	4.4	4.4

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1e: Baseline table (Oseltamivir, excluding influenza)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	507,867	
Demographics		
Mean Age (Years)	34.0	19.5
Age: 00-17 (Years)	140,516	27.7%
Age: 18-24 (Years)	43,571	8.6%
Age: 25-40 (Years)	121,229	23.9%
Age: 41-64 (Years)	187,834	37.0%
Age: 65+ (Years)	14,717	2.9%
Sex (Female)	287,829	56.7%
Sex (Male)	220,038	43.3%
Year (2018)	30,071	5.9%
Year (2019)	258,364	50.9%
Year (2020)	184,262	36.3%
Year (2021)	20,981	4.1%
Year (2022)	14,189	2.8%
Recorded history of:		
Prior combined comorbidity score ³	0.4	1.2
Acquired Hypothyroidism	38,286	7.5%
Acute Myocardial Infarction	1,313	0.3%
Alzheimer's Disease	1,009	0.2%
Alzheimer's Disease, Related Disorders, or Senile Dementia	2,962	0.6%
Anemia	30,930	6.1%
Asthma	43,980	8.7%
Atrial Fibrillation	5,596	1.1%
Benign Prostatic Hyperplasia	8,128	1.6%
Breast Cancer	5,015	1.0%
Cataracts	17,070	3.4%
Chronic Kidney Disease	23,993	4.7%
Chronic Obstructive Pulmonary Disease	19,005	3.7%
Colorectal Cancer	995	0.2%
Depression	51,383	10.1%
Diabetes	34,576	6.8%
Endometrial Cancer	413	0.1%
Glaucoma	11,491	2.3%
Heart Failure	4,496	0.9%
Hip / Pelvic Fracture	633	0.1%
Hyperlipidemia	90,594	17.8%
Hypertension	88,946	17.5%
Ischemic Heart Disease	13,468	2.7%
Lung Cancer	633	0.1%
Osteoporosis	5,196	1.0%
Prostate Cancer	1,623	0.3%
Rheumatoid Arthritis / Osteoarthritis	45,573	9.0%
Stroke / Transient Ischemic Attack	3,837	0.8%

Table 1e: Baseline table (Oseltamivir, excluding influenza)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	10.4	13.2
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.1	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.2	7.7
Mean number of filled prescriptions	14.3	20.1
Mean number of generics	5.4	5.4
Mean number of unique drug classes	5.0	4.7
¹ All metrics based on total number of unique patients ² Value represents standard deviation where no % follows the value ³ The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. <i>J Clin Epidemiol.</i> 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. <i>Med Care.</i> 2017;55(12):1046-1051).		

Table 1f: Baseline table (Oseltamivir, including influenza)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	623,402	
Demographics		
Mean Age (Years)	27.2	19.3
Age: 00-17 (Years)	270,431	43.4%
Age: 18-24 (Years)	57,849	9.3%
Age: 25-40 (Years)	121,627	19.5%
Age: 41-64 (Years)	165,328	26.5%
Age: 65+ (Years)	8,167	1.3%
Sex (Female)	333,448	53.5%
Sex (Male)	289,954	46.5%
Year (2018)	33,602	5.4%
Year (2019)	329,071	52.8%
Year (2020)	216,208	34.7%
Year (2021)	24,574	3.9%
Year (2022)	19,947	3.2%
Recorded history of:		
Prior combined comorbidity score ³	0.3	1.0
Acquired Hypothyroidism	31,413	5.0%
Acute Myocardial Infarction	1,120	0.2%
Alzheimer's Disease	180	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	750	0.1%
Anemia	28,452	4.6%
Asthma	58,628	9.4%
Atrial Fibrillation	4,129	0.7%
Benign Prostatic Hyperplasia	6,527	1.0%
Breast Cancer	3,716	0.6%
Cataracts	13,141	2.1%
Chronic Kidney Disease	23,048	3.7%
Chronic Obstructive Pulmonary Disease	20,234	3.2%
Colorectal Cancer	720	0.1%
Depression	50,000	8.0%
Diabetes	32,337	5.2%
Endometrial Cancer	338	0.1%
Glaucoma	9,715	1.6%
Heart Failure	3,396	0.5%
Hip / Pelvic Fracture	435	0.1%
Hyperlipidemia	79,278	12.7%
Hypertension	80,135	12.9%
Ischemic Heart Disease	10,635	1.7%
Lung Cancer	378	0.1%
Osteoporosis	3,562	0.6%
Prostate Cancer	1,315	0.2%
Rheumatoid Arthritis / Osteoarthritis	38,362	6.2%
Stroke / Transient Ischemic Attack	2,765	0.4%

Table 1f: Baseline table (Oseltamivir, including influenza)		
Characteristic ¹	N/Mean	%/Std Dev ²
Health Service Utilization Intensity:		
Mean number of ambulatory encounters (AV)	9.2	12.2
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.0	0.3
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	1.6	6.2
Mean number of filled prescriptions	10.5	15.9
Mean number of generics	4.4	4.7
Mean number of unique drug classes	4.0	4.2

¹All metrics based on total number of unique patients
²Value represents standard deviation where no % follows the value
³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).



Table 2a: Distribution of cumulative exposure duration, by length categories, in days												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,067	100.0	7	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,314	100.0	11,309	100.0	5	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	21,914	100.0	21,912	100.0	2	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,314	99.9	677	0.1	15	0.0	1	0.0	0	0.0
Oseltamivir , excluding influenza	507,867	100.0	507,372	99.9	479	0.1	15	0.0	1	0.0	0	0.0
Oseltamivir , including influenza	623,402	100.0	623,192	100.0	209	0.0	1	0.0	0	0.0	0	0.0

Table 2b: Distribution of cumulative exposure duration, by length categories, in days, by sex												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,067	100.0	7	100.0	0	0.0	0	0.0	0	0.0
Female	17,570	53.1	17,566	53.1	4	57.1	0	0.0	0	0.0	0	0.0
Male	15,504	46.9	15,501	46.9	3	42.9	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	11,314	100.0	11,309	100.0	5	100.0	0	0.0	0	0.0	0	0.0
Female	6,127	54.2	6,125	54.2	2	40.0	0	0.0	0	0.0	0	0.0
Male	5,187	45.8	5,184	45.8	3	60.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	21,914	100.0	21,912	100.0	2	100.0	0	0.0	0	0.0	0	0.0
Female	11,528	52.6	11,526	52.6	2	100.0	0	0.0	0	0.0	0	0.0
Male	10,386	47.4	10,386	47.4	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,314	100.0	677	100.0	15	100.0	1	100.0	0	0.0
Female	609,922	54.9	609,575	54.9	339	50.1	8	53.3	0	0.0	0	0.0
Male	501,085	45.1	500,739	45.1	338	49.9	7	46.7	1	100.0	0	0.0
Oseltamivir, excluding influenza	507,867	100.0	507,372	100.0	479	100.0	15	100.0	1	100.0	0	0.0
Female	287,829	56.7	287,571	56.7	250	52.2	8	53.3	0	0.0	0	0.0
Male	220,038	43.3	219,801	43.3	229	47.8	7	46.7	1	100.0	0	0.0
Oseltamivir, including influenza	623,402	100.0	623,192	100.0	209	100.0	1	100.0	0	0.0	0	0.0
Female	333,448	53.5	333,352	53.5	95	45.5	1	100.0	0	0.0	0	0.0
Male	289,954	46.5	289,840	46.5	114	54.5	0	0.0	0	0.0	0	0.0

Table 2c: Distribution of cumulative exposure duration, by length categories, in days, by age group (Years)												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,067	100.0	7	100.0	0	0.0	0	0.0	0	0.0
00-17	6,052	18.3	6,052	18.3	0	0.0	0	0.0	0	0.0	0	0.0
18-24	4,529	13.7	4,528	13.7	1	14.3	0	0.0	0	0.0	0	0.0
25-40	8,746	26.4	8,745	26.4	1	14.3	0	0.0	0	0.0	0	0.0
41-64	13,361	40.4	13,358	40.4	3	42.9	0	0.0	0	0.0	0	0.0
65+	386	1.2	384	1.2	2	28.6	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	11,314	100.0	11,309	100.0	5	100.0	0	0.0	0	0.0	0	0.0
00-17	1,548	13.7	1,548	13.7	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1,449	12.8	1,449	12.8	0	0.0	0	0.0	0	0.0	0	0.0
25-40	2,977	26.3	2,977	26.3	0	0.0	0	0.0	0	0.0	0	0.0
41-64	5,120	45.3	5,117	45.2	3	60.0	0	0.0	0	0.0	0	0.0
65+	220	1.9	218	1.9	2	40.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	21,914	100.0	21,912	100.0	2	100.0	0	0.0	0	0.0	0	0.0
00-17	4,537	20.7	4,537	20.7	0	0.0	0	0.0	0	0.0	0	0.0
18-24	3,106	14.2	3,105	14.2	1	50.0	0	0.0	0	0.0	0	0.0
25-40	5,804	26.5	5,803	26.5	1	50.0	0	0.0	0	0.0	0	0.0
41-64	8,300	37.9	8,300	37.9	0	0.0	0	0.0	0	0.0	0	0.0
65+	167	0.8	167	0.8	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,314	100.0	677	100.0	15	100.0	1	100.0	0	0.0
00-17	401,050	36.1	400,649	36.1	401	59.2	0	0.0	0	0.0	0	0.0
18-24	99,680	9.0	99,665	9.0	15	2.2	0	0.0	0	0.0	0	0.0
25-40	239,254	21.5	239,210	21.5	42	6.2	2	13.3	0	0.0	0	0.0
41-64	348,305	31.4	348,206	31.4	86	12.7	12	80.0	1	100.0	0	0.0
65+	22,718	2.0	22,584	2.0	133	19.6	1	6.7	0	0.0	0	0.0
Oseltamivir, excluding influenza	507,867	100.0	507,372	100.0	479	100.0	15	100.0	1	100.0	0	0.0
00-17	140,516	27.7	140,284	27.6	232	48.4	0	0.0	0	0.0	0	0.0
18-24	43,571	8.6	43,559	8.6	12	2.5	0	0.0	0	0.0	0	0.0
25-40	121,229	23.9	121,195	23.9	32	6.7	2	13.3	0	0.0	0	0.0
41-64	187,834	37.0	187,744	37.0	77	16.1	12	80.0	1	100.0	0	0.0
65+	14,717	2.9	14,590	2.9	126	26.3	1	6.7	0	0.0	0	0.0
Oseltamivir, including influenza	623,402	100.0	623,192	100.0	209	100.0	1	100.0	0	0.0	0	0.0
00-17	270,431	43.4	270,252	43.4	179	85.6	0	0.0	0	0.0	0	0.0
18-24	57,849	9.3	57,846	9.3	3	1.4	0	0.0	0	0.0	0	0.0
25-40	121,627	19.5	121,615	19.5	11	5.3	1	100.0	0	0.0	0	0.0
41-64	165,328	26.5	165,319	26.5	9	4.3	0	0.0	0	0.0	0	0.0
65+	8,167	1.3	8,160	1.3	7	3.3	0	0.0	0	0.0	0	0.0

Table 3a: Descriptive statistics of cumulative exposure duration, all episodes, in days

Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	33,074	1.16	1.82	1	1	1	1	90
Baloxavir, excluding influenza	11,314	1.22	2.17	1	1	1	1	90
Baloxavir, including influenza	21,914	1.13	1.60	1	1	1	1	90
Oseltamivir	1,111,007	6.36	3.06	1	5	5	6	450
Oseltamivir, excluding influenza	507,867	7.22	3.66	1	5	5	10	450
Oseltamivir, including influenza	623,402	5.66	2.24	1	5	5	5	105

Table 3b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex									
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	33,074	1.16	1.82	1	1	1	1	90	
Female	17,570	1.17	1.95	1	1	1	1	90	
Male	15,504	1.15	1.67	1	1	1	1	32	
Baloxavir , excluding influenza	11,314	1.22	2.17	1	1	1	1	90	
Female	6,127	1.23	2.32	1	1	1	1	90	
Male	5,187	1.22	1.98	1	1	1	1	32	
Baloxavir , including influenza	21,914	1.13	1.60	1	1	1	1	90	
Female	11,528	1.13	1.71	1	1	1	1	90	
Male	10,386	1.12	1.47	1	1	1	1	30	
Oseltamivir	1,111,007	6.36	3.06	1	5	5	6	450	
Female	609,922	6.36	3.03	1	5	5	6	255	
Male	501,085	6.36	3.10	1	5	5	6	450	
Oseltamivir , excluding influenza	507,867	7.22	3.66	1	5	5	10	450	
Female	287,829	7.20	3.59	1	5	5	10	255	
Male	220,038	7.24	3.75	1	5	5	10	450	
Oseltamivir , including influenza	623,402	5.66	2.24	1	5	5	5	105	
Female	333,448	5.64	2.20	1	5	5	5	105	
Male	289,954	5.69	2.29	1	5	5	5	90	

Table 3c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (Years)									
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	33,074	1.16	1.82	1	1	1	1	90	
00-17	6,052	1.10	1.02	1	1	1	1	30	
18-24	4,529	1.12	1.46	1	1	1	1	32	
25-40	8,746	1.14	1.86	1	1	1	1	90	
41-64	13,361	1.19	2.02	1	1	1	1	90	
65+	386	1.95	4.84	1	1	1	1	32	
Baloxavir , excluding influenza	11,314	1.22	2.17	1	1	1	1	90	
00-17	1,548	1.10	0.80	1	1	1	1	30	
18-24	1,449	1.15	1.55	1	1	1	1	30	
25-40	2,977	1.17	1.85	1	1	1	1	30	
41-64	5,120	1.28	2.53	1	1	1	1	90	
65+	220	2.05	5.18	1	1	1	1	32	
Baloxavir , including influenza	21,914	1.13	1.60	1	1	1	1	90	
00-17	4,537	1.10	1.09	1	1	1	1	30	
18-24	3,106	1.11	1.41	1	1	1	1	32	
25-40	5,804	1.13	1.85	1	1	1	1	90	
41-64	8,300	1.13	1.61	1	1	1	1	30	
65+	167	1.81	4.35	1	1	1	1	30	
Oseltamivir	1,111,007	6.36	3.06	1	5	5	6	450	
00-17	401,050	6.73	3.36	1	5	5	8	90	
18-24	99,680	5.75	2.17	1	5	5	5	63	
25-40	239,254	6.19	2.74	1	5	5	5	155	
41-64	348,305	6.17	2.90	1	5	5	5	450	
65+	22,718	7.25	5.02	1	5	5	10	91	
Oseltamivir , excluding influenza	507,867	7.22	3.66	1	5	5	10	450	
00-17	140,516	7.86	3.99	1	5	6	10	90	
18-24	43,571	6.35	2.71	1	5	5	7	50	
25-40	121,229	7.05	3.28	1	5	5	10	155	
41-64	187,834	6.96	3.52	1	5	5	10	450	
65+	14,717	8.47	5.68	1	5	5	10	91	
Oseltamivir , including influenza	623,402	5.66	2.24	1	5	5	5	105	
00-17	270,431	6.14	2.80	1	5	5	6	90	
18-24	57,849	5.29	1.49	1	5	5	5	63	
25-40	121,627	5.34	1.68	1	5	5	5	105	
41-64	165,328	5.28	1.53	1	5	5	5	67	
65+	8,167	5.07	2.20	1	5	5	5	81	



Table 4a: Distribution of first exposure episode duration, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,072	100.0	2	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	11,314	100.0	11,313	100.0	1	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	21,914	100.0	21,913	100.0	1	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,864	100.0	138	0.0	5	0.0	0	0.0	0	0.0
Oseltamivir, excluding influenza	507,867	100.0	507,780	100.0	82	0.0	5	0.0	0	0.0	0	0.0
Oseltamivir, including influenza	623,402	100.0	623,343	100.0	59	0.0	0	0.0	0	0.0	0	0.0



Table 4b: Distribution of first exposure episode duration, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,072	100.0	2	100.0	0	0.0	0	0.0	0	0.0
Female	17,570	53.1	17,568	53.1	2	100.0	0	0.0	0	0.0	0	0.0
Male	15,504	46.9	15,504	46.9	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	11,314	100.0	11,313	100.0	1	100.0	0	0.0	0	0.0	0	0.0
Female	6,127	54.2	6,126	54.2	1	100.0	0	0.0	0	0.0	0	0.0
Male	5,187	45.8	5,187	45.8	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	21,914	100.0	21,913	100.0	1	100.0	0	0.0	0	0.0	0	0.0
Female	11,528	52.6	11,527	52.6	1	100.0	0	0.0	0	0.0	0	0.0
Male	10,386	47.4	10,386	47.4	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,864	100.0	138	100.0	5	100.0	0	0.0	0	0.0
Female	609,922	54.9	609,852	54.9	69	50.0	1	20.0	0	0.0	0	0.0
Male	501,085	45.1	501,012	45.1	69	50.0	4	80.0	0	0.0	0	0.0
Oseltamivir, excluding influenza	507,867	100.0	507,780	100.0	82	100.0	5	100.0	0	0.0	0	0.0
Female	287,829	56.7	287,782	56.7	46	56.1	1	20.0	0	0.0	0	0.0
Male	220,038	43.3	219,998	43.3	36	43.9	4	80.0	0	0.0	0	0.0
Oseltamivir, including influenza	623,402	100.0	623,343	100.0	59	100.0	0	0.0	0	0.0	0	0.0
Female	333,448	53.5	333,423	53.5	25	42.4	0	0.0	0	0.0	0	0.0
Male	289,954	46.5	289,920	46.5	34	57.6	0	0.0	0	0.0	0	0.0



Table 4c: Distribution of first exposure episode duration, by length categories, in days, by age group (Years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	33,074	100.0	33,072	100.0	2	100.0	0	0.0	0	0.0	0	0.0
00-17	6,052	18.3	6,052	18.3	0	0.0	0	0.0	0	0.0	0	0.0
18-24	4,529	13.7	4,529	13.7	0	0.0	0	0.0	0	0.0	0	0.0
25-40	8,746	26.4	8,745	26.4	1	50.0	0	0.0	0	0.0	0	0.0
41-64	13,361	40.4	13,360	40.4	1	50.0	0	0.0	0	0.0	0	0.0
65+	386	1.2	386	1.2	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,314	100.0	11,313	100.0	1	100.0	0	0.0	0	0.0	0	0.0
00-17	1,548	13.7	1,548	13.7	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1,449	12.8	1,449	12.8	0	0.0	0	0.0	0	0.0	0	0.0
25-40	2,977	26.3	2,977	26.3	0	0.0	0	0.0	0	0.0	0	0.0
41-64	5,120	45.3	5,119	45.2	1	100.0	0	0.0	0	0.0	0	0.0
65+	220	1.9	220	1.9	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	21,914	100.0	21,913	100.0	1	100.0	0	0.0	0	0.0	0	0.0
00-17	4,537	20.7	4,537	20.7	0	0.0	0	0.0	0	0.0	0	0.0
18-24	3,106	14.2	3,106	14.2	0	0.0	0	0.0	0	0.0	0	0.0
25-40	5,804	26.5	5,803	26.5	1	100.0	0	0.0	0	0.0	0	0.0
41-64	8,300	37.9	8,300	37.9	0	0.0	0	0.0	0	0.0	0	0.0
65+	167	0.8	167	0.8	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,111,007	100.0	1,110,864	100.0	138	100.0	5	100.0	0	0.0	0	0.0
00-17	401,050	36.1	400,959	36.1	91	65.9	0	0.0	0	0.0	0	0.0
18-24	99,680	9.0	99,674	9.0	6	4.3	0	0.0	0	0.0	0	0.0
25-40	239,254	21.5	239,238	21.5	16	11.6	0	0.0	0	0.0	0	0.0
41-64	348,305	31.4	348,283	31.4	17	12.3	5	100.0	0	0.0	0	0.0
65+	22,718	2.0	22,710	2.0	8	5.8	0	0.0	0	0.0	0	0.0
Oseltamivir , excluding influenza	507,867	100.0	507,780	100.0	82	100.0	5	100.0	0	0.0	0	0.0
00-17	140,516	27.7	140,469	27.7	47	57.3	0	0.0	0	0.0	0	0.0
18-24	43,571	8.6	43,567	8.6	4	4.9	0	0.0	0	0.0	0	0.0
25-40	121,229	23.9	121,219	23.9	10	12.2	0	0.0	0	0.0	0	0.0
41-64	187,834	37.0	187,815	37.0	14	17.1	5	100.0	0	0.0	0	0.0
65+	14,717	2.9	14,710	2.9	7	8.5	0	0.0	0	0.0	0	0.0
Oseltamivir , including influenza	623,402	100.0	623,343	100.0	59	100.0	0	0.0	0	0.0	0	0.0
00-17	270,431	43.4	270,385	43.4	46	78.0	0	0.0	0	0.0	0	0.0
18-24	57,849	9.3	57,847	9.3	2	3.4	0	0.0	0	0.0	0	0.0
25-40	121,627	19.5	121,620	19.5	7	11.9	0	0.0	0	0.0	0	0.0
41-64	165,328	26.5	165,325	26.5	3	5.1	0	0.0	0	0.0	0	0.0
65+	8,167	1.3	8,166	1.3	1	1.7	0	0.0	0	0.0	0	0.0

Table 5a: Descriptive statistics of first exposure episode duration, in days

Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	33,074	1.12	1.78	1	1	1	1	90
Baloxavir, excluding influenza	11,314	1.17	2.10	1	1	1	1	90
Baloxavir, including influenza	21,914	1.10	1.59	1	1	1	1	90
Oseltamivir	1,111,007	5.91	2.18	1	5	5	5	180
Oseltamivir, excluding influenza	507,867	6.68	2.67	1	5	5	10	180
Oseltamivir, including influenza	623,402	5.28	1.39	1	5	5	5	90

Table 5b: Descriptive statistics of first exposure episode duration, in days, by sex									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	33,074	1.12	1.78	1	1	1	1	90	
Female	17,570	1.13	1.92	1	1	1	1	90	
Male	15,504	1.11	1.61	1	1	1	1	30	
Baloxavir , excluding influenza	11,314	1.17	2.10	1	1	1	1	90	
Female	6,127	1.18	2.28	1	1	1	1	90	
Male	5,187	1.15	1.86	1	1	1	1	30	
Baloxavir , including influenza	21,914	1.10	1.59	1	1	1	1	90	
Female	11,528	1.10	1.70	1	1	1	1	90	
Male	10,386	1.09	1.46	1	1	1	1	30	
Oseltamivir	1,111,007	5.91	2.18	1	5	5	5	180	
Female	609,922	5.90	2.16	1	5	5	5	120	
Male	501,085	5.91	2.21	1	5	5	5	180	
Oseltamivir , excluding influenza	507,867	6.68	2.67	1	5	5	10	180	
Female	287,829	6.66	2.62	1	5	5	10	120	
Male	220,038	6.71	2.73	1	5	5	10	180	
Oseltamivir , including influenza	623,402	5.28	1.39	1	5	5	5	90	
Female	333,448	5.26	1.35	1	5	5	5	90	
Male	289,954	5.30	1.44	1	5	5	5	90	

Table 5c: Descriptive statistics of first exposure episode duration, in days, by age group (Years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	33,074	1.12	1.78	1	1	1	1	90	
00-17	6,052	1.06	1.00	1	1	1	1	30	
18-24	4,529	1.10	1.44	1	1	1	1	30	
25-40	8,746	1.11	1.85	1	1	1	1	90	
41-64	13,361	1.15	1.97	1	1	1	1	90	
65+	386	1.81	4.56	1	1	1	1	30	
Baloxavir , excluding influenza	11,314	1.17	2.10	1	1	1	1	90	
00-17	1,548	1.05	0.76	1	1	1	1	30	
18-24	1,449	1.11	1.53	1	1	1	1	30	
25-40	2,977	1.13	1.84	1	1	1	1	30	
41-64	5,120	1.21	2.44	1	1	1	1	90	
65+	220	1.81	4.71	1	1	1	1	30	
Baloxavir , including influenza	21,914	1.10	1.59	1	1	1	1	90	
00-17	4,537	1.06	1.07	1	1	1	1	30	
18-24	3,106	1.09	1.39	1	1	1	1	30	
25-40	5,804	1.10	1.85	1	1	1	1	90	
41-64	8,300	1.11	1.60	1	1	1	1	30	
65+	167	1.80	4.35	1	1	1	1	30	
Oseltamivir	1,111,007	5.91	2.18	1	5	5	5	180	
00-17	401,050	6.11	2.40	1	5	5	6	90	
18-24	99,680	5.46	1.61	1	5	5	5	63	
25-40	239,254	5.80	1.97	1	5	5	5	90	
41-64	348,305	5.82	2.05	1	5	5	5	180	
65+	22,718	6.63	3.34	1	5	5	10	42	
Oseltamivir , excluding influenza	507,867	6.68	2.67	1	5	5	10	180	
00-17	140,516	7.14	2.97	1	5	5	10	90	
18-24	43,571	6.01	2.15	1	5	5	5	50	
25-40	121,229	6.56	2.43	1	5	5	10	90	
41-64	187,834	6.50	2.52	1	5	5	10	180	
65+	14,717	7.60	3.68	1	5	5	10	42	
Oseltamivir , including influenza	623,402	5.28	1.39	1	5	5	5	90	
00-17	270,431	5.59	1.84	1	5	5	5	90	
18-24	57,849	5.05	0.82	1	5	5	5	63	
25-40	121,627	5.05	0.84	1	5	5	5	90	
41-64	165,328	5.04	0.81	1	5	5	5	67	
65+	8,167	4.87	1.41	1	5	5	5	39	



Table 6a: Distribution of second and subsequent exposure episode duration, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	1,086	100.0	1,086	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	534	100.0	534	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	562	100.0	562	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	81,539	100.0	81,520	100.0	16	0.0	3	0.0	0	0.0	0	0.0
Oseltamivir, excluding influenza	42,300	100.0	42,286	100.0	11	0.0	3	0.0	0	0.0	0	0.0
Oseltamivir, including influenza	40,507	100.0	40,501	100.0	5	0.0	1	0.0	0	0.0	0	0.0



Table 6b: Distribution of second and subsequent exposure episode duration, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	1,086	100.0	1,086	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	572	52.7	572	52.7	0	0.0	0	0.0	0	0.0	0	0.0
Male	514	47.3	514	47.3	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	534	100.0	534	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	272	50.9	272	50.9	0	0.0	0	0.0	0	0.0	0	0.0
Male	262	49.1	262	49.1	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	562	100.0	562	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	309	55.0	309	55.0	0	0.0	0	0.0	0	0.0	0	0.0
Male	253	45.0	253	45.0	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	81,539	100.0	81,520	100.0	16	100.0	3	100.0	0	0.0	0	0.0
Female	45,130	55.3	45,120	55.3	8	50.0	2	66.7	0	0.0	0	0.0
Male	36,409	44.7	36,400	44.7	8	50.0	1	33.3	0	0.0	0	0.0
Oseltamivir, excluding influenza	42,300	100.0	42,286	100.0	11	100.0	3	100.0	0	0.0	0	0.0
Female	24,267	57.4	24,260	57.4	5	45.5	2	66.7	0	0.0	0	0.0
Male	18,033	42.6	18,026	42.6	6	54.5	1	33.3	0	0.0	0	0.0
Oseltamivir , including influenza	40,507	100.0	40,501	100.0	5	100.0	1	100.0	0	0.0	0	0.0
Female	21,593	53.3	21,589	53.3	3	60.0	1	100.0	0	0.0	0	0.0
Male	18,914	46.7	18,912	46.7	2	40.0	0	0.0	0	0.0	0	0.0

Table 6c: Distribution of second and subsequent exposure episode duration, by length categories, in days, by age group (Years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	1,086	100.0	1,086	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	244	22.5	244	22.5	0	0.0	0	0.0	0	0.0	0	0.0
18-24	123	11.3	123	11.3	0	0.0	0	0.0	0	0.0	0	0.0
25-40	239	22.0	239	22.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	457	42.1	457	42.1	0	0.0	0	0.0	0	0.0	0	0.0
65+	23	2.1	23	2.1	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	534	100.0	534	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	81	15.2	81	15.2	0	0.0	0	0.0	0	0.0	0	0.0
18-24	48	9.0	48	9.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	105	19.7	105	19.7	0	0.0	0	0.0	0	0.0	0	0.0
41-64	279	52.2	279	52.2	0	0.0	0	0.0	0	0.0	0	0.0
65+	21	3.9	21	3.9	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	562	100.0	562	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	164	29.2	164	29.2	0	0.0	0	0.0	0	0.0	0	0.0
18-24	78	13.9	78	13.9	0	0.0	0	0.0	0	0.0	0	0.0
25-40	134	23.8	134	23.8	0	0.0	0	0.0	0	0.0	0	0.0
41-64	184	32.7	184	32.7	0	0.0	0	0.0	0	0.0	0	0.0
65+	2	0.4	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	81,539	100.0	81,520	100.0	16	100.0	3	100.0	0	0.0	0	0.0
00-17	39,511	48.5	39,504	48.5	7	43.8	0	0.0	0	0.0	0	0.0
18-24	5,170	6.3	5,170	6.3	0	0.0	0	0.0	0	0.0	0	0.0
25-40	14,978	18.4	14,975	18.4	2	12.5	1	33.3	0	0.0	0	0.0
41-64	20,225	24.8	20,218	24.8	5	31.3	2	66.7	0	0.0	0	0.0
65+	1,655	2.0	1,653	2.0	2	12.5	0	0.0	0	0.0	0	0.0
Oseltamivir, excluding influenza	42,300	100.0	42,286	100.0	11	100.0	3	100.0	0	0.0	0	0.0
00-17	15,575	36.8	15,571	36.8	4	36.4	0	0.0	0	0.0	0	0.0
18-24	2,555	6.0	2,555	6.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	9,149	21.6	9,147	21.6	1	9.1	1	33.3	0	0.0	0	0.0
41-64	13,593	32.1	13,586	32.1	5	45.5	2	66.7	0	0.0	0	0.0
65+	1,428	3.4	1,427	3.4	1	9.1	0	0.0	0	0.0	0	0.0
Oseltamivir , including influenza	40,507	100.0	40,501	100.0	5	100.0	1	100.0	0	0.0	0	0.0
00-17	24,665	60.9	24,662	60.9	3	60.0	0	0.0	0	0.0	0	0.0
18-24	2,684	6.6	2,684	6.6	0	0.0	0	0.0	0	0.0	0	0.0
25-40	6,020	14.9	6,018	14.9	1	20.0	1	100.0	0	0.0	0	0.0
41-64	6,898	17.0	6,898	17.0	0	0.0	0	0.0	0	0.0	0	0.0
65+	240	0.6	239	0.6	1	20.0	0	0.0	0	0.0	0	0.0

Table 7a: Descriptive statistics of second and subsequent exposure episode duration, in days

Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	1,086	1.13	1.54	1	1	1	1	30
Baloxavir, excluding influenza	534	1.22	2.18	1	1	1	1	30
Baloxavir, including influenza	562	1.04	0.24	1	1	1	1	5
Oseltamivir	81,539	6.20	2.72	1	5	5	6	270
Oseltamivir, excluding influenza	42,300	6.46	3.11	1	5	5	8	270
Oseltamivir, including influenza	40,507	5.92	2.26	1	5	5	5	100

Table 7b: Descriptive statistics of second and subsequent exposure episode duration, in days, by sex									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	1,086	1.13	1.54	1	1	1	1	30	
Female	572	1.08	1.23	1	1	1	1	30	
Male	514	1.17	1.82	1	1	1	1	30	
Baloxavir , excluding influenza	534	1.22	2.18	1	1	1	1	30	
Female	272	1.13	1.76	1	1	1	1	30	
Male	262	1.31	2.54	1	1	1	1	30	
Baloxavir , including influenza	562	1.04	0.24	1	1	1	1	5	
Female	309	1.04	0.28	1	1	1	1	5	
Male	253	1.04	0.19	1	1	1	1	2	
Oseltamivir	81,539	6.20	2.72	1	5	5	6	270	
Female	45,130	6.18	2.58	1	5	5	6	125	
Male	36,409	6.22	2.89	1	5	5	6	270	
Oseltamivir, excluding influenza	42,300	6.46	3.11	1	5	5	8	270	
Female	24,267	6.43	2.85	1	5	5	8	125	
Male	18,033	6.51	3.42	1	5	5	10	270	
Oseltamivir , including influenza	40,507	5.92	2.26	1	5	5	5	100	
Female	21,593	5.89	2.28	1	5	5	5	100	
Male	18,914	5.95	2.25	1	5	5	5	40	

Table 7c: Descriptive statistics of second and subsequent exposure episode duration, in days, by age group (Years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	1,086	1.13	1.54	1	1	1	1	30	
00-17	244	1.03	0.28	1	1	1	1	5	
18-24	123	1.05	0.22	1	1	1	1	2	
25-40	239	1.01	0.09	1	1	1	1	2	
41-64	457	1.20	1.93	1	1	1	1	30	
65+	23	2.35	6.03	1	1	1	1	30	
Baloxavir , excluding influenza	534	1.22	2.18	1	1	1	1	30	
00-17	81	1.01	0.11	1	1	1	1	2	
18-24	48	1.06	0.24	1	1	1	1	2	
25-40	105	1.01	0.10	1	1	1	1	2	
41-64	279	1.28	2.46	1	1	1	1	30	
65+	21	2.48	6.31	1	1	1	1	30	
Baloxavir , including influenza	562	1.04	0.24	1	1	1	1	5	
00-17	164	1.04	0.33	1	1	1	1	5	
18-24	78	1.04	0.19	1	1	1	1	2	
25-40	134	1.01	0.09	1	1	1	1	2	
41-64	184	1.07	0.25	1	1	1	1	2	
65+	2	1.00	0.00	1	1	1	1	1	
Oseltamivir	81,539	6.20	2.72	1	5	5	6	270	
00-17	39,511	6.22	2.49	1	5	5	6	75	
18-24	5,170	5.52	1.72	1	5	5	5	20	
25-40	14,978	6.21	2.45	1	5	5	7	100	
41-64	20,225	6.11	3.17	1	5	5	5	270	
65+	1,655	8.61	4.90	1	5	5	14	80	
Oseltamivir , excluding influenza	42,300	6.46	3.11	1	5	5	8	270	
00-17	15,575	6.49	2.69	1	5	5	8	75	
18-24	2,555	5.70	1.92	1	5	5	5	20	
25-40	9,149	6.48	2.69	1	5	5	10	100	
41-64	13,593	6.31	3.62	1	5	5	7	270	
65+	1,428	8.92	4.67	1	5	10	14	52	
Oseltamivir , including influenza	40,507	5.92	2.26	1	5	5	5	100	
00-17	24,665	6.06	2.35	1	5	5	6	40	
18-24	2,684	5.35	1.49	1	5	5	5	20	
25-40	6,020	5.81	2.29	1	5	5	5	100	
41-64	6,898	5.71	1.87	1	5	5	5	20	
65+	240	6.68	5.68	1	5	5	7	80	



Table 8a: Distribution of all episode durations, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,160	100.0	34,158	100.0	2	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, excluding influenza	11,848	100.0	11,847	100.0	1	0.0	0	0.0	0	0.0	0	0.0
Baloxavir, including influenza	22,476	100.0	22,475	100.0	1	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,192,546	100.0	1,192,384	100.0	154	0.0	8	0.0	0	0.0	0	0.0
Oseltamivir, excluding influenza	550,167	100.0	550,066	100.0	93	0.0	8	0.0	0	0.0	0	0.0
Oseltamivir, including influenza	663,909	100.0	663,844	100.0	64	0.0	1	0.0	0	0.0	0	0.0

Table 8b: Distribution of all episode durations, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,160	100.0	34,158	100.0	2	100.0	0	0.0	0	0.0	0	0.0
Female	18,142	53.1	18,140	53.1	2	100.0	0	0.0	0	0.0	0	0.0
Male	16,018	46.9	16,018	46.9	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,848	100.0	11,847	100.0	1	100.0	0	0.0	0	0.0	0	0.0
Female	6,399	54.0	6,398	54.0	1	100.0	0	0.0	0	0.0	0	0.0
Male	5,449	46.0	5,449	46.0	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	22,476	100.0	22,475	100.0	1	100.0	0	0.0	0	0.0	0	0.0
Female	11,837	52.7	11,836	52.7	1	100.0	0	0.0	0	0.0	0	0.0
Male	10,639	47.3	10,639	47.3	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,192,546	100.0	1,192,384	100.0	154	100.0	8	100.0	0	0.0	0	0.0
Female	655,052	54.9	654,972	54.9	77	50.0	3	37.5	0	0.0	0	0.0
Male	537,494	45.1	537,412	45.1	77	50.0	5	62.5	0	0.0	0	0.0
Oseltamivir , excluding influenza	550,167	100.0	550,066	100.0	93	100.0	8	100.0	0	0.0	0	0.0
Female	312,096	56.7	312,042	56.7	51	54.8	3	37.5	0	0.0	0	0.0
Male	238,071	43.3	238,024	43.3	42	45.2	5	62.5	0	0.0	0	0.0
Oseltamivir , including influenza	663,909	100.0	663,844	100.0	64	100.0	1	100.0	0	0.0	0	0.0
Female	355,041	53.5	355,012	53.5	28	43.8	1	100.0	0	0.0	0	0.0
Male	308,868	46.5	308,832	46.5	36	56.3	0	0.0	0	0.0	0	0.0



Table 8c: Distribution of all episode durations, by length categories, in days, by age group (Years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,160	100.0	34,158	100.0	2	100.0	0	0.0	0	0.0	0	0.0
00-17	6,296	18.4	6,296	18.4	0	0.0	0	0.0	0	0.0	0	0.0
18-24	4,652	13.6	4,652	13.6	0	0.0	0	0.0	0	0.0	0	0.0
25-40	8,985	26.3	8,984	26.3	1	50.0	0	0.0	0	0.0	0	0.0
41-64	13,818	40.5	13,817	40.5	1	50.0	0	0.0	0	0.0	0	0.0
65+	409	1.2	409	1.2	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,848	100.0	11,847	100.0	1	100.0	0	0.0	0	0.0	0	0.0
00-17	1,629	13.7	1,629	13.8	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1,497	12.6	1,497	12.6	0	0.0	0	0.0	0	0.0	0	0.0
25-40	3,082	26.0	3,082	26.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	5,399	45.6	5,398	45.6	1	100.0	0	0.0	0	0.0	0	0.0
65+	241	2.0	241	2.0	0	0.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	22,476	100.0	22,475	100.0	1	100.0	0	0.0	0	0.0	0	0.0
00-17	4,701	20.9	4,701	20.9	0	0.0	0	0.0	0	0.0	0	0.0
18-24	3,184	14.2	3,184	14.2	0	0.0	0	0.0	0	0.0	0	0.0
25-40	5,938	26.4	5,937	26.4	1	100.0	0	0.0	0	0.0	0	0.0
41-64	8,484	37.7	8,484	37.7	0	0.0	0	0.0	0	0.0	0	0.0
65+	169	0.8	169	0.8	0	0.0	0	0.0	0	0.0	0	0.0
Oseltamivir	1,192,546	100.0	1,192,384	100.0	154	100.0	8	100.0	0	0.0	0	0.0
00-17	440,561	36.9	440,463	36.9	98	63.6	0	0.0	0	0.0	0	0.0
18-24	104,850	8.8	104,844	8.8	6	3.9	0	0.0	0	0.0	0	0.0
25-40	254,232	21.3	254,213	21.3	18	11.7	1	12.5	0	0.0	0	0.0
41-64	368,530	30.9	368,501	30.9	22	14.3	7	87.5	0	0.0	0	0.0
65+	24,373	2.0	24,363	2.0	10	6.5	0	0.0	0	0.0	0	0.0
Oseltamivir , excluding influenza	550,167	100.0	550,066	100.0	93	100.0	8	100.0	0	0.0	0	0.0
00-17	156,091	28.4	156,040	28.4	51	54.8	0	0.0	0	0.0	0	0.0
18-24	46,126	8.4	46,122	8.4	4	4.3	0	0.0	0	0.0	0	0.0
25-40	130,378	23.7	130,366	23.7	11	11.8	1	12.5	0	0.0	0	0.0
41-64	201,427	36.6	201,401	36.6	19	20.4	7	87.5	0	0.0	0	0.0
65+	16,145	2.9	16,137	2.9	8	8.6	0	0.0	0	0.0	0	0.0
Oseltamivir , including influenza	663,909	100.0	663,844	100.0	64	100.0	1	100.0	0	0.0	0	0.0
00-17	295,096	44.4	295,047	44.4	49	76.6	0	0.0	0	0.0	0	0.0
18-24	60,533	9.1	60,531	9.1	2	3.1	0	0.0	0	0.0	0	0.0
25-40	127,647	19.2	127,638	19.2	8	12.5	1	100.0	0	0.0	0	0.0
41-64	172,226	25.9	172,223	25.9	3	4.7	0	0.0	0	0.0	0	0.0
65+	8,407	1.3	8,405	1.3	2	3.1	0	0.0	0	0.0	0	0.0

Table 9a: Descriptive statistics of all exposure episode durations, in days

Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	34,160	1.12	1.78	1	1	1	1	90
Baloxavir, excluding influenza	11,848	1.17	2.10	1	1	1	1	90
Baloxavir, including influenza	22,476	1.10	1.57	1	1	1	1	90
Oseltamivir	1,192,546	5.93	2.22	1	5	5	5	270
Oseltamivir, excluding influenza	550,167	6.67	2.71	1	5	5	10	270
Oseltamivir, including influenza	663,909	5.32	1.47	1	5	5	5	100

Table 9b: Descriptive statistics of all exposure episode durations, in days, by sex									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	34,160	1.12	1.78	1	1	1	1	90	
Female	18,142	1.13	1.91	1	1	1	1	90	
Male	16,018	1.11	1.62	1	1	1	1	30	
Baloxavir , excluding influenza	11,848	1.17	2.10	1	1	1	1	90	
Female	6,399	1.18	2.26	1	1	1	1	90	
Male	5,449	1.16	1.90	1	1	1	1	30	
Baloxavir , including influenza	22,476	1.10	1.57	1	1	1	1	90	
Female	11,837	1.10	1.68	1	1	1	1	90	
Male	10,639	1.09	1.45	1	1	1	1	30	
Oseltamivir	1,192,546	5.93	2.22	1	5	5	5	270	
Female	655,052	5.92	2.19	1	5	5	5	125	
Male	537,494	5.93	2.26	1	5	5	5	270	
Oseltamivir , excluding influenza	550,167	6.67	2.71	1	5	5	10	270	
Female	312,096	6.64	2.64	1	5	5	10	125	
Male	238,071	6.70	2.79	1	5	5	10	270	
Oseltamivir , including influenza	663,909	5.32	1.47	1	5	5	5	100	
Female	355,041	5.29	1.43	1	5	5	5	100	
Male	308,868	5.34	1.51	1	5	5	5	90	

Table 9c: Descriptive statistics of all exposure episode durations, in days, by age group (Years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	34,160	1.12	1.78	1	1	1	1	90	
00-17	6,296	1.05	0.98	1	1	1	1	30	
18-24	4,652	1.09	1.42	1	1	1	1	30	
25-40	8,985	1.11	1.82	1	1	1	1	90	
41-64	13,818	1.15	1.97	1	1	1	1	90	
65+	409	1.84	4.65	1	1	1	1	30	
Baloxavir, excluding influenza	11,848	1.17	2.10	1	1	1	1	90	
00-17	1,629	1.04	0.74	1	1	1	1	30	
18-24	1,497	1.11	1.51	1	1	1	1	30	
25-40	3,082	1.13	1.81	1	1	1	1	30	
41-64	5,399	1.21	2.44	1	1	1	1	90	
65+	241	1.87	4.85	1	1	1	1	30	
Baloxavir, including influenza	22,476	1.10	1.57	1	1	1	1	90	
00-17	4,701	1.06	1.05	1	1	1	1	30	
18-24	3,184	1.09	1.37	1	1	1	1	30	
25-40	5,938	1.10	1.83	1	1	1	1	90	
41-64	8,484	1.11	1.59	1	1	1	1	30	
65+	169	1.79	4.33	1	1	1	1	30	
Oseltamivir	1,192,546	5.93	2.22	1	5	5	5	270	
00-17	440,561	6.12	2.41	1	5	5	6	90	
18-24	104,850	5.46	1.62	1	5	5	5	63	
25-40	254,232	5.83	2.00	1	5	5	5	100	
41-64	368,530	5.83	2.13	1	5	5	5	270	
65+	24,373	6.76	3.51	1	5	5	10	80	
Oseltamivir, excluding influenza	550,167	6.67	2.71	1	5	5	10	270	
00-17	156,091	7.08	2.95	1	5	5	10	90	
18-24	46,126	5.99	2.14	1	5	5	5	50	
25-40	130,378	6.56	2.45	1	5	5	10	100	
41-64	201,427	6.49	2.61	1	5	5	10	270	
65+	16,145	7.72	3.80	1	5	5	10	52	
Oseltamivir, including influenza	663,909	5.32	1.47	1	5	5	5	100	
00-17	295,096	5.63	1.89	1	5	5	5	90	
18-24	60,533	5.06	0.87	1	5	5	5	63	
25-40	127,647	5.09	0.97	1	5	5	5	100	
41-64	172,226	5.07	0.88	1	5	5	5	67	
65+	8,407	4.92	1.71	1	5	5	5	80	



Table 10a: Distribution of days supplied per dispensing, by length categories										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,210	100.0	34,208	100.0	0	0.0	2	0.0	0	0.0
Baloxavir, excluding influenza	11,871	100.0	11,870	100.0	0	0.0	1	0.0	0	0.0
Baloxavir, including influenza	22,504	100.0	22,503	100.0	0	0.0	1	0.0	0	0.0
Oseltamivir	1,197,677	100.0	1,197,552	100.0	98	0.0	25	0.0	2	0.0
Oseltamivir, excluding influenza	552,847	100.0	552,772	100.0	57	0.0	16	0.0	2	0.0
Oseltamivir, including influenza	666,478	100.0	666,423	100.0	46	0.0	9	0.0	0	0.0

Table 10b: Distribution of days supplied per dispensing, by length categories, by sex										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,210	100.0	34,208	100.0	0	0.0	2	100.0	0	0.0
Female	18,165	53.1	18,163	53.1	0	0.0	2	100.0	0	0.0
Male	16,045	46.9	16,045	46.9	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,871	100.0	11,870	100.0	0	0.0	1	100.0	0	0.0
Female	6,411	54.0	6,410	54.0	0	0.0	1	100.0	0	0.0
Male	5,460	46.0	5,460	46.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	22,504	100.0	22,503	100.0	0	0.0	1	100.0	0	0.0
Female	11,849	52.7	11,848	52.7	0	0.0	1	100.0	0	0.0
Male	10,655	47.3	10,655	47.3	0	0.0	0	0.0	0	0.0
Oseltamivir	1,197,677	100.0	1,197,552	100.0	98	100.0	25	100.0	2	100.0
Female	657,825	54.9	657,763	54.9	49	50.0	13	52.0	0	0.0
Male	539,852	45.1	539,789	45.1	49	50.0	12	48.0	2	100.0
Oseltamivir , excluding influenza	552,847	100.0	552,772	100.0	57	100.0	16	100.0	2	100.0
Female	313,625	56.7	313,584	56.7	34	59.6	7	43.8	0	0.0
Male	239,222	43.3	239,188	43.3	23	40.4	9	56.3	2	100.0
Oseltamivir , including influenza	666,478	100.0	666,423	100.0	46	100.0	9	100.0	0	0.0
Female	356,346	53.5	356,321	53.5	19	41.3	6	66.7	0	0.0
Male	310,132	46.5	310,102	46.5	27	58.7	3	33.3	0	0.0

Table 10c: Distribution of days supplied per dispensing, by length categories, by age group (Years)										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Baloxavir	34,210	100.0	34,208	100.0	0	0.0	2	100.0	0	0.0
00-17	6,306	18.4	6,306	18.4	0	0.0	0	0.0	0	0.0
18-24	4,661	13.6	4,661	13.6	0	0.0	0	0.0	0	0.0
25-40	8,995	26.3	8,994	26.3	0	0.0	1	50.0	0	0.0
41-64	13,838	40.5	13,837	40.4	0	0.0	1	50.0	0	0.0
65+	410	1.2	410	1.2	0	0.0	0	0.0	0	0.0
Baloxavir , excluding influenza	11,871	100.0	11,870	100.0	0	0.0	1	100.0	0	0.0
00-17	1,631	13.7	1,631	13.7	0	0.0	0	0.0	0	0.0
18-24	1,499	12.6	1,499	12.6	0	0.0	0	0.0	0	0.0
25-40	3,086	26.0	3,086	26.0	0	0.0	0	0.0	0	0.0
41-64	5,413	45.6	5,412	45.6	0	0.0	1	100.0	0	0.0
65+	242	2.0	242	2.0	0	0.0	0	0.0	0	0.0
Baloxavir , including influenza	22,504	100.0	22,503	100.0	0	0.0	1	100.0	0	0.0
00-17	4,709	20.9	4,709	20.9	0	0.0	0	0.0	0	0.0
18-24	3,192	14.2	3,192	14.2	0	0.0	0	0.0	0	0.0
25-40	5,944	26.4	5,943	26.4	0	0.0	1	100.0	0	0.0
41-64	8,490	37.7	8,490	37.7	0	0.0	0	0.0	0	0.0
65+	169	0.8	169	0.8	0	0.0	0	0.0	0	0.0
Oseltamivir	1,197,677	100.0	1,197,552	100.0	98	100.0	25	100.0	2	100.0
00-17	443,304	37.0	443,228	37.0	69	70.4	7	28.0	0	0.0
18-24	105,097	8.8	105,092	8.8	5	5.1	0	0.0	0	0.0
25-40	254,869	21.3	254,850	21.3	14	14.3	5	20.0	0	0.0
41-64	369,611	30.9	369,589	30.9	8	8.2	12	48.0	2	100.0
65+	24,796	2.1	24,793	2.1	2	2.0	1	4.0	0	0.0
Oseltamivir , excluding influenza	552,847	100.0	552,772	100.0	57	100.0	16	100.0	2	100.0
00-17	157,113	28.4	157,074	28.4	37	64.9	2	12.5	0	0.0
18-24	46,252	8.4	46,249	8.4	3	5.3	0	0.0	0	0.0
25-40	130,805	23.7	130,792	23.7	10	17.5	3	18.8	0	0.0
41-64	202,169	36.6	202,150	36.6	6	10.5	11	68.8	2	100.0
65+	16,508	3.0	16,507	3.0	1	1.8	0	0.0	0	0.0
Oseltamivir , including influenza	666,478	100.0	666,423	100.0	46	100.0	9	100.0	0	0.0
00-17	296,899	44.5	296,860	44.5	34	73.9	5	55.6	0	0.0
18-24	60,659	9.1	60,657	9.1	2	4.3	0	0.0	0	0.0
25-40	127,871	19.2	127,862	19.2	7	15.2	2	22.2	0	0.0
41-64	172,582	25.9	172,579	25.9	2	4.3	1	11.1	0	0.0
65+	8,467	1.3	8,465	1.3	1	2.2	1	11.1	0	0.0

Table 11a: Descriptive statistics of days supplied per dispensing

Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	34,210	1.12	1.78	1	1	1	1	90
Baloxavir, excluding influenza	11,871	1.17	2.10	1	1	1	1	90
Baloxavir, including influenza	22,504	1.10	1.57	1	1	1	1	90
Oseltamivir	1,197,677	5.90	2.15	1	5	5	5	100
Oseltamivir, excluding influenza	552,847	6.63	2.61	1	5	5	10	100
Oseltamivir, including influenza	666,478	5.30	1.42	1	5	5	5	90

Table 11b: Descriptive statistics of days supplied per dispensing, by sex									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	34,210	1.12	1.78	1	1	1	1	90	
Female	18,165	1.13	1.90	1	1	1	1	90	
Male	16,045	1.11	1.62	1	1	1	1	30	
Baloxavir , excluding influenza	11,871	1.17	2.10	1	1	1	1	90	
Female	6,411	1.17	2.25	1	1	1	1	90	
Male	5,460	1.16	1.90	1	1	1	1	30	
Baloxavir , including influenza	22,504	1.10	1.57	1	1	1	1	90	
Female	11,849	1.10	1.68	1	1	1	1	90	
Male	10,655	1.09	1.44	1	1	1	1	30	
Oseltamivir	1,197,677	5.90	2.15	1	5	5	5	100	
Female	657,825	5.90	2.13	1	5	5	5	90	
Male	539,852	5.90	2.17	1	5	5	5	100	
Oseltamivir , excluding influenza	552,847	6.63	2.61	1	5	5	10	100	
Female	313,625	6.61	2.58	1	5	5	10	90	
Male	239,222	6.66	2.66	1	5	5	10	100	
Oseltamivir , including influenza	666,478	5.30	1.42	1	5	5	5	90	
Female	356,346	5.28	1.38	1	5	5	5	90	
Male	310,132	5.32	1.47	1	5	5	5	90	

Table 11c: Descriptive statistics of days supplied per dispensing, by age group (Years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Baloxavir	34,210	1.12	1.78	1	1	1	1	90	
00-17	6,306	1.05	0.98	1	1	1	1	30	
18-24	4,661	1.09	1.42	1	1	1	1	30	
25-40	8,995	1.11	1.82	1	1	1	1	90	
41-64	13,838	1.15	1.96	1	1	1	1	90	
65+	410	1.83	4.64	1	1	1	1	30	
Baloxavir , excluding influenza	11,871	1.17	2.10	1	1	1	1	90	
00-17	1,631	1.04	0.74	1	1	1	1	30	
18-24	1,499	1.11	1.50	1	1	1	1	30	
25-40	3,086	1.13	1.81	1	1	1	1	30	
41-64	5,413	1.21	2.43	1	1	1	1	90	
65+	242	1.86	4.84	1	1	1	1	30	
Baloxavir , including influenza	22,504	1.10	1.57	1	1	1	1	90	
00-17	4,709	1.06	1.05	1	1	1	1	30	
18-24	3,192	1.08	1.37	1	1	1	1	30	
25-40	5,944	1.10	1.82	1	1	1	1	90	
41-64	8,490	1.11	1.59	1	1	1	1	30	
65+	169	1.79	4.33	1	1	1	1	30	
Oseltamivir	1,197,677	5.90	2.15	1	5	5	5	100	
00-17	443,304	6.09	2.35	1	5	5	6	90	
18-24	105,097	5.45	1.59	1	5	5	5	58	
25-40	254,869	5.81	1.97	1	5	5	5	90	
41-64	369,611	5.82	2.03	1	5	5	5	100	
65+	24,796	6.65	3.28	1	5	5	10	80	
Oseltamivir , excluding influenza	552,847	6.63	2.61	1	5	5	10	100	
00-17	157,113	7.03	2.88	1	5	5	10	90	
18-24	46,252	5.98	2.11	1	5	5	5	50	
25-40	130,805	6.53	2.42	1	5	5	10	90	
41-64	202,169	6.46	2.47	1	5	5	10	100	
65+	16,508	7.55	3.53	1	5	5	10	32	
Oseltamivir , including influenza	666,478	5.30	1.42	1	5	5	5	90	
00-17	296,899	5.59	1.83	1	5	5	5	90	
18-24	60,659	5.05	0.83	1	5	5	5	58	
25-40	127,871	5.08	0.93	1	5	5	5	90	
41-64	172,582	5.06	0.85	1	5	5	5	67	
65+	8,467	4.89	1.66	1	5	5	5	80	

Table 12a: Descriptive statistics of the length of the first gap between treatment episodes, in days

Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	971	277.93	259.73	1	49	262	379	1,159
Baloxavir, excluding influenza	453	238.53	237.15	1	41	182	359	1,159
Baloxavir, including influenza	527	312.28	273.20	1	57	292	410	1,144
Oseltamivir	74,509	313.31	240.16	1	112	313	369	1,241
Oseltamivir, excluding influenza	38,125	301.56	239.25	1	87	308	368	1,241
Oseltamivir, including influenza	37,559	323.38	242.45	1	144	316	371	1,241

Table 12b: Descriptive statistics of the length of the first gap between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	971	277.93	259.73	1	49	262	379	1,159
Female	512	282.26	248.00	1	57	286	375	1,159
Male	459	273.10	272.40	1	41	227	383	1,159
Baloxavir , excluding influenza	453	238.53	237.15	1	41	182	359	1,159
Female	237	243.27	236.40	1	45	187	365	1,159
Male	216	233.33	238.40	1	41	154	348	1,159
Baloxavir , including influenza	527	312.28	273.20	1	57	292	410	1,144
Female	283	314.49	252.96	1	66	311	393	1,144
Male	244	309.71	295.46	1	46	272	432	1,111
Oseltamivir	74,509	313.31	240.16	1	112	313	369	1,241
Female	41,173	311.48	237.17	1	112	313	369	1,215
Male	33,336	315.57	243.80	1	112	313	369	1,241
Oseltamivir , excluding influenza	38,125	301.56	239.25	1	87	308	368	1,241
Female	21,843	300.52	235.82	1	89	309	368	1,215
Male	16,282	302.95	243.78	1	85	308	367	1,241
Oseltamivir , including influenza	37,559	323.38	242.45	1	144	316	371	1,241
Female	20,008	322.02	240.34	1	140	316	371	1,205
Male	17,551	324.92	244.82	1	148	315	371	1,241

Table 12c: Descriptive statistics of the length of the first gap between treatment episodes, in days, by age group (Years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	971	277.93	259.73	1	49	262	379	1,159
00-17	230	304.19	287.92	1	42	279	392	1,144
18-24	115	324.06	271.72	1	59	309	422	1,076
25-40	225	289.23	279.60	1	49	241	387	1,159
41-64	384	248.71	223.40	1	48	246	359	1,144
65+	17	121.18	119.96	2	29	63	273	306
Baloxavir , excluding influenza	453	238.53	237.15	1	41	182	359	1,159
00-17	74	212.96	242.49	1	31	83	354	1,035
18-24	45	309.93	255.55	1	60	307	410	1,076
25-40	98	258.74	265.96	1	43	168	367	1,159
41-64	221	231.98	219.96	1	41	197	353	1,144
65+	15	115.00	117.22	2	19	63	273	306
Baloxavir , including influenza	527	312.28	273.20	1	57	292	410	1,144
00-17	157	346.71	297.39	1	60	321	622	1,144
18-24	73	335.11	281.38	1	68	312	612	1,046
25-40	127	312.75	288.53	1	55	262	446	1,076
41-64	168	271.54	228.19	1	56	275	365	989
65+	2	167.50	181.73	39	39	168	296	296
Oseltamivir	74,509	313.31	240.16	1	112	313	369	1,241
00-17	36,166	317.44	244.55	1	113	314	366	1,241
18-24	4,832	344.06	263.61	1	135	315	397	1,176
25-40	13,900	311.04	235.50	1	115	312	372	1,241
41-64	18,221	306.09	230.23	1	114	311	372	1,201
65+	1,390	216.29	176.06	1	38	255	340	1,113
Oseltamivir , excluding influenza	38,125	301.56	239.25	1	87	308	368	1,241
00-17	14,111	306.54	250.89	1	76	310	365	1,241
18-24	2,354	332.72	263.32	1	109	311	393	1,176
25-40	8,440	304.29	233.31	1	101	311	371	1,199
41-64	12,037	296.31	227.52	1	96	307	368	1,200
65+	1,183	213.98	175.50	1	38	256	339	1,113
Oseltamivir , including influenza	37,559	323.38	242.45	1	144	316	371	1,241
00-17	22,739	322.06	242.52	1	148	316	367	1,238
18-24	2,545	354.03	264.51	1	162	318	402	1,164
25-40	5,637	320.89	239.85	1	138	313	374	1,241
41-64	6,419	321.54	235.69	1	145	317	380	1,201
65+	219	222.36	178.32	1	43	248	343	1,084

Table 13a: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	115	225.83	224.53	1	44	150	349	815
Baloxavir, excluding influenza	81	211.85	216.65	1	42	140	312	815
Baloxavir, including influenza	35	252.91	241.60	10	53	166	433	747
Oseltamivir	7,030	269.18	265.77	1	46	197	366	1,167
Oseltamivir, excluding influenza	4,175	263.16	259.84	1	46	191	358	1,167
Oseltamivir, including influenza	2,948	277.18	273.51	1	47	200	394	1,152

Table 13b: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	115	225.83	224.53	1	44	150	349	815
Female	60	260.28	237.45	7	54	180	431	747
Male	55	188.24	205.12	1	33	80	302	815
Baloxavir , excluding influenza	81	211.85	216.65	1	42	140	312	815
Female	35	265.86	229.13	7	52	230	467	697
Male	46	170.76	199.46	1	33	68	294	815
Baloxavir , including influenza	35	252.91	241.60	10	53	166	433	747
Female	26	244.38	251.51	20	53	128	395	747
Male	9	277.56	222.43	10	73	232	433	615
Oseltamivir	7,030	269.18	265.77	1	46	197	366	1,167
Female	3,957	270.28	266.13	1	47	199	372	1,152
Male	3,073	267.76	265.33	1	45	192	359	1,167
Oseltamivir , excluding influenza	4,175	263.16	259.84	1	46	191	358	1,167
Female	2,424	263.95	261.19	1	46	194	361	1,125
Male	1,751	262.07	258.02	1	46	191	354	1,167
Oseltamivir , including influenza	2,948	277.18	273.51	1	47	200	394	1,152
Female	1,585	278.83	273.09	1	49	203	412	1,152
Male	1,363	275.26	274.07	1	44	197	375	1,099

Table 13c: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by age group (Years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	115	225.83	224.53	1	44	150	349	815
00-17	14	317.00	243.79	6	71	294	584	694
18-24	8	252.88	246.75	15	48	187	432	675
25-40	14	307.79	260.00	7	71	189	559	678
41-64	73	197.58	212.72	3	42	89	294	815
65+	6	129.50	127.67	1	1	113	238	312
Baloxavir , excluding influenza	81	211.85	216.65	1	42	140	312	815
00-17	7	310.29	251.38	6	71	285	584	694
18-24	3	265.67	230.34	15	15	314	468	468
25-40	7	416.14	275.83	7	52	490	660	678
41-64	58	181.05	199.45	3	41	74	281	815
65+	6	129.50	127.67	1	1	113	238	312
Baloxavir , including influenza	35	252.91	241.60	10	53	166	433	747
00-17	7	323.71	255.87	10	53	349	615	672
18-24	5	245.20	282.54	42	54	60	395	675
25-40	7	199.43	207.34	42	71	157	203	651
41-64	16	247.75	252.81	20	43	133	452	747
65+	0	-	-	-	-	-	-	-
Osetamivir	7,030	269.18	265.77	1	46	197	366	1,167
00-17	3,345	280.67	283.73	1	43	198	389	1,134
18-24	338	327.35	277.26	1	72	268	635	1,030
25-40	1,078	300.64	270.62	1	63	248	422	1,152
41-64	2,004	235.67	233.05	1	46	158	343	1,167
65+	265	175.18	156.45	1	42	143	297	826
Osetamivir , excluding influenza	4,175	263.16	259.84	1	46	191	358	1,167
00-17	1,464	289.38	284.78	1	44	234	386	1,134
18-24	201	325.79	278.48	1	77	267	633	1,030
25-40	709	299.49	272.35	1	61	248	440	1,115
41-64	1,556	228.03	230.53	1	43	141	335	1,167
65+	245	173.11	154.94	1	42	129	295	826
Osetamivir , including influenza	2,948	277.18	273.51	1	47	200	394	1,152
00-17	1,926	274.46	283.08	1	41	159	413	1,125
18-24	139	327.55	275.45	2	68	282	636	965
25-40	383	300.80	265.34	1	77	249	394	1,152
41-64	479	257.80	239.27	1	61	204	356	1,059
65+	21	203.90	172.55	6	27	247	301	586

Table 14a: Descriptive statistics of the length of all gaps between treatment episodes, in days

Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	1,086	272.41	256.64	1	48	247	375	1,159
Baloxavir, excluding influenza	534	234.49	234.15	1	41	167	354	1,159
Baloxavir, including influenza	562	308.58	271.53	1	57	288	410	1,144
Oseltamivir	81,539	309.50	242.79	1	97	309	369	1,241
Oseltamivir, excluding influenza	42,300	297.77	241.63	1	80	304	367	1,241
Oseltamivir, including influenza	40,507	320.02	245.13	1	116	313	371	1,241

Table 14b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	1,086	272.41	256.64	1	48	247	375	1,159
Female	572	279.95	246.81	1	56	275	376	1,159
Male	514	264.02	267.14	1	41	199	375	1,159
Baloxavir , excluding influenza	534	234.49	234.15	1	41	167	354	1,159
Female	272	246.18	235.18	1	50	193	366	1,159
Male	262	222.34	232.91	1	40	135	342	1,159
Baloxavir , including influenza	562	308.58	271.53	1	57	288	410	1,144
Female	309	308.59	253.18	1	61	301	393	1,144
Male	253	308.57	292.89	1	46	270	433	1,111
Oseltamivir	81,539	309.50	242.79	1	97	309	369	1,241
Female	45,130	307.87	240.13	1	97	309	369	1,215
Male	36,409	311.53	246.04	1	97	309	369	1,241
Oseltamivir , excluding influenza	42,300	297.77	241.63	1	80	304	367	1,241
Female	24,267	296.87	238.72	1	82	304	368	1,215
Male	18,033	298.98	245.49	1	78	304	367	1,241
Oseltamivir , including influenza	40,507	320.02	245.13	1	116	313	371	1,241
Female	21,593	318.85	243.15	1	115	313	372	1,205
Male	18,914	321.34	247.37	1	118	313	371	1,241

Table 14c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (Years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Baloxavir	1,086	272.41	256.64	1	48	247	375	1,159
00-17	244	304.92	285.15	1	44	283	393	1,144
18-24	123	319.43	269.81	1	59	309	422	1,076
25-40	239	290.31	278.01	1	49	237	394	1,159
41-64	457	240.54	222.29	1	45	221	353	1,144
65+	23	123.35	119.10	1	19	75	273	312
Baloxavir , excluding influenza	534	234.49	234.15	1	41	167	354	1,159
00-17	81	221.37	243.22	1	34	100	354	1,035
18-24	48	307.17	252.02	1	59	310	416	1,076
25-40	105	269.24	268.17	1	44	182	382	1,159
41-64	279	221.39	216.50	1	41	166	342	1,144
65+	21	119.14	117.21	1	19	75	238	312
Baloxavir , including influenza	562	308.58	271.53	1	57	288	410	1,144
00-17	164	345.73	295.08	1	60	321	619	1,144
18-24	78	329.35	280.49	1	59	311	612	1,046
25-40	134	306.83	285.39	1	58	250	423	1,076
41-64	184	269.47	229.79	1	55	272	371	989
65+	2	167.50	181.73	39	39	168	296	296
Oseltamivir	81,539	309.50	242.79	1	97	309	369	1,241
00-17	39,511	314.33	248.32	1	94	311	366	1,241
18-24	5,170	342.96	264.52	1	126	314	400	1,176
25-40	14,978	310.29	238.20	1	107	310	373	1,241
41-64	20,225	299.11	231.46	1	97	306	371	1,201
65+	1,655	209.70	173.68	1	38	242	335	1,113
Oseltamivir , excluding influenza	42,300	297.77	241.63	1	80	304	367	1,241
00-17	15,575	304.93	254.31	1	70	306	365	1,241
18-24	2,555	332.17	264.49	1	105	309	397	1,176
25-40	9,149	303.92	236.55	1	94	309	372	1,199
41-64	13,593	288.50	228.89	1	85	300	366	1,200
65+	1,428	206.97	172.79	1	38	234	333	1,113
Oseltamivir , including influenza	40,507	320.02	245.13	1	116	313	371	1,241
00-17	24,665	318.34	246.25	1	106	313	367	1,238
18-24	2,684	352.66	265.10	1	146	317	407	1,164
25-40	6,020	319.61	241.58	1	126	311	375	1,241
41-64	6,898	317.11	236.48	1	127	314	379	1,201
65+	240	220.74	177.54	1	42	248	341	1,084



Table 15: Counts of reason for censoring, all episodes and first episode										
	Total		Disenrollment		Evidence of death		DP/Query end date		Episode end	
	N	%	N	%	N	%	N	%	N	%
Exposures										
Baloxavir	34,160	100.0	60	0.2	0	0.0	26	0.1	34,160	100.0
Baloxavir, excluding influenza	11,848	100.0	20	0.2	0	0.0	8	0.1	11,848	100.0
Baloxavir, including influenza	22,476	100.0	40	0.2	0	0.0	18	0.1	22,476	100.0
Oseltamivir	1,192,546	100.0	11,911	1.0	0	0.0	4,066	0.3	1,192,546	100.0
Oseltamivir, excluding influenza	550,167	100.0	6,151	1.1	0	0.0	1,798	0.3	550,167	100.0
Oseltamivir, including influenza	663,909	100.0	6,108	0.9	0	0.0	2,445	0.4	663,909	100.0
Patients' First Episode										
Baloxavir	33,074	100.0	60	0.2	0	0.0	26	0.1	33,074	100.0
Baloxavir, excluding influenza	11,314	100.0	20	0.2	0	0.0	8	0.1	11,314	100.0
Baloxavir, including influenza	21,914	100.0	40	0.2	0	0.0	18	0.1	21,914	100.0
Oseltamivir	1,111,007	100.0	10,760	1.0	0	0.0	3,528	0.3	1,111,007	100.0
Oseltamivir, excluding influenza	507,867	100.0	5,580	1.1	0	0.0	1,558	0.3	507,867	100.0
Oseltamivir, including influenza	623,402	100.0	5,514	0.9	0	0.0	2,135	0.3	623,402	100.0

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Baloxavir	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	41,240 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	33,074 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	33,074 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	33,074 (0.1%)
Baloxavir , excluding influenza	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	41,240 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	33,074 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	11,314 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	11,314 (0.0%)
Baloxavir , including influenza	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	41,240 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	41,240 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	33,074 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	21,914 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	21,914 (0.1%)
Osetamivir	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,459,207 (3.3%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	1,459,207 (3.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,111,007 (2.5%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	1,111,007 (2.5%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	1,111,007 (2.5%)
Osetamivir , excluding influenza	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,459,207 (3.3%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	1,459,207 (3.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,111,007 (2.5%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	507,867 (1.2%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	507,867 (1.2%)
Osetamivir , including influenza	

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	43,817,953 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	41,634,052 (95.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	41,634,052 (95.0%)
Exclusion - Members must satisfy the age range condition within the query period	41,633,997 (95.0%)
Exclusion - Members must meet chart availability criterion within the query period	41,633,997 (95.0%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	41,633,997 (95.0%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,459,207 (3.3%)
Exclusion - Members must have at least one cohort episode index date within the age range condition	1,459,207 (3.3%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,457,911 (3.3%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	1,111,007 (2.5%)
Exclusion - Members must have at least one cohort episode satisfying all exclusion and inclusion criteria	623,402 (1.4%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	623,402 (1.4%)

Appendix A. Dates of Available Data for Each Data Partner (DP) up to Request End Date (03/31/2022) as of Query Distribution Date

Data Partner (Masked)	Start Date	End Date
DP01	01/01/2010	03/31/2022

Global Values

Enrollment Criteria: **Medical and Drug Coverage**

Enrollment Gap (Days): **45**

Age Groups (Years): **00-17, 18-24, 25-40, 41-64, 65+**

Reporting Output: **All tables**

Query Period: **10/24/2018-03/31/2022**

Baseline Characteristics Table: **Yes**

Baseline Evaluation Window (Day): **-365,-1**

#	Cohort Name	Index Exposure	Pre-Index Enrollment Period (Days)	Washout Period (Days)	Treatment Episode Gap (Days)	Treatment Episode Extension (Days)	Inclusion/Exclusion	Criteria	Criteria Definition	Evaluation Period Start (Day)	Evaluation Period End (Day)
1	Baloxavir	Baloxavir ^[1]	365	183	0	0	--	--	--	--	--
2	Oseltamivir	Oseltamivir ^[2]	365	183	0	0	--	--	--	--	--
3	Baloxavir excl influenza	Baloxavir ^[3]	365	183	0	0	Exclusion	Influenza	Influenz a ^[4]	-10	0
4	Oseltamivir excl influenza	Oseltamivir ^[5]	365	183	0	0	Exclusion	Influenza	Influenz a ^[6]	-10	0
5	Baloxavir incl influenza	Baloxavir ^[7]	365	183	0	0	Inclusion	Influenza	Influenz a ^[8]	-10	0
6	Oseltamivir incl influenza	Oseltamivir ^[9]	365	183	0	0	Inclusion	Influenza	Influenz a ^[10]	-10	0

ICD-9,ICD-10,HCPCS AND CPT are provided by Optum360
NDCs are checked against First Data Bank's MedKnowledge.

Appendix of Generic Names and Chronic Conditions

- (1) See Appendix C
- (2) See Appendix C
- (3) See Appendix C
- (4) See Appendix E and G
- (5) See Appendix C
- (6) See Appendix E and G
- (7) See Appendix C
- (8) See Appendix D and F
- (9) See Appendix C
- (10) See Appendix D and F

Baseline Characteristics Table

Acquired Hypothyroidism	Chronic Kidney Disease	Hypertension
Acute Myocardial Infarction	Chronic Obstructive Pulmonary Disease	Ischemic Heart Disease
Alzheimer's Disease	Colorectal Cancer	Lung Cancer
Alzheimer's Disease, Related Disorders, or Senile Dementia	Depression	Osteoporosis
Anemia	Diabetes	Prostate Cancer
Asthma	Endometrial Cancer	Rheumatoid Arthritis / Osteoarthritis
Atrial Fibrillation	Glaucoma	Stroke / Transient Ischemic Attack
Benign Prostatic Hyperplasia	Heart Failure	
Breast Cancer	Hip / Pelvic Fracture	
Cataracts	Hyperlipidemia	

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module

- Age Groups** - Age groups of members included in the cohort. Strata also used for reporting purposes.
- Ambulatory Visit (AV)** - A care setting value including visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Baseline Characteristics Table** - Optional table containing general characteristics of study population, including background rates of 27 chronic conditions from the CMS Chronic Condition Warehouse (see above if table requested). Users define an evaluation period for the presence of baseline characteristics.
- Care Setting** - Type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.
- Charlson/Elixhauser Combined Comorbidity Score** - Calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
- Cohort Definition** - Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using the washout period.
- Emergency Department (ED)** - A care setting value including ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Enrollment Criteria** - Type of coverage required during enrollment period. By default, all patients must have medical and drug coverage.
- Enrollment Gap** - Allowed gap between coverage periods.
- Episodes** - Treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
- Inclusion/Exclusion** - Contains the comprehensive set of codes used to define additional cohort inclusion and/or exclusion criteria (e.g., restrict cohort to individuals with evidence of a pre-existing condition 183 days before the index date). Criteria could be defined with complex algorithms (e.g., diagnosis codes and drug codes) defined under Criteria Definition.
- Inpatient Hospital Stay (IP)** - A care setting value including all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS)** - A care setting value including hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA)** - A care setting value including other non-overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.
- Principal Diagnosis (PDX)** - Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
- Query Period** - The period of time which patients can contribute index-defining exposure/events. Data prior to the start date may be used to determine enrollment, washout, and other cohort inclusion criteria.
- Treatment Episode Extension** - The episode extension adds the selected number of days to the end of an episode to count as exposed time.
- Treatment Episode Gap** - The maximum number of days allowed between two dispensings to consider them part of the same episode.
- Washout Period** - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures of Interest in this Request

Generic Name	Brand Name
Oseltamivir	
Oseltamivir Phosphate	Tamiflu
Baloxavir	
Baloxavir Marboxil	Xofluza

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
Influenza			
J09.X3	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with gastrointestinal manifestations
J09.X9	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with other manifestations
J09.X2	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with other respiratory manifestations
J09.X1	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with pneumonia
J10.81	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with encephalopathy
J10.82	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with myocarditis
J10.89	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other manifestations
J10.08	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other specified pneumonia
J10.83	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with otitis media
J10.01	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia
J10.00	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with unspecified type of pneumonia
J11.81	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with encephalopathy
J11.82	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with myocarditis
J11.89	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other manifestations
J11.83	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with otitis media
J11.08	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with specified pneumonia
J11.00	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with unspecified type of pneumonia
J10	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus
J10.2	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with gastrointestinal manifestations
J10.8	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other manifestations
J10.1	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other respiratory manifestations
J10.0	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with pneumonia
J09	Diagnosis	ICD-10-CM	Influenza due to certain identified influenza viruses
J09.X	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus
J11	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus
J11.2	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with gastrointestinal manifestations

Appendix D. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Inclusion Criteria in this Request

Code	Code Category	Code Type	Description
J11.8	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other manifestations
J11.1	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other respiratory manifestations
J11.0	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with pneumonia

Appendix E. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Code Category	Code Type	Description
Influenza			
J09.X3	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with gastrointestinal manifestations
J09.X9	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with other manifestations
J09.X2	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with other respiratory manifestations
J09.X1	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus with pneumonia
J10.81	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with encephalopathy
J10.82	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with myocarditis
J10.89	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other manifestations
J10.08	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other specified pneumonia
J10.83	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with otitis media
J10.01	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia
J10.00	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with unspecified type of pneumonia
J11.81	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with encephalopathy
J11.82	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with myocarditis
J11.89	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other manifestations
J11.83	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with otitis media
J11.08	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with specified pneumonia
J11.00	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with unspecified type of pneumonia
J10	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus
J10.2	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with gastrointestinal manifestations
J10.8	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other manifestations
J10.1	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with other respiratory manifestations
J10.0	Diagnosis	ICD-10-CM	Influenza due to other identified influenza virus with pneumonia
J09	Diagnosis	ICD-10-CM	Influenza due to certain identified influenza viruses
J09.X	Diagnosis	ICD-10-CM	Influenza due to identified novel influenza A virus
J11	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus
J11.2	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with gastrointestinal manifestations

Appendix E. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Exclusion Criteria in this Request

Code	Code Category	Code Type	Description
J11.8	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other manifestations
J11.1	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with other respiratory manifestations
J11.0	Diagnosis	ICD-10-CM	Influenza due to unidentified influenza virus with pneumonia

Appendix F. List of Polymerase Chain Reaction (PCR) Tests Used to Define Inclusion Criteria for this Request

Test Name	Test Category	Specimen Source	Test Result
Influenza			
Influenza Virus A	PCR	nasopharyngeal swab	Positive
Influenza Virus A	PCR	nasopharyngeal wash	Positive
Influenza Virus A	PCR	nasal wash	Positive
Influenza Virus A	PCR	other	Positive
Influenza Virus A	PCR	unknown or missing	Positive
Influenza Virus A and B	PCR	nasopharyngeal swab	Positive
Influenza Virus A and B	PCR	nasopharyngeal wash	Positive
Influenza Virus A and B	PCR	nasal wash	Positive
Influenza Virus A and B	PCR	other	Positive
Influenza Virus A and B	PCR	unknown or missing	Positive
Influenza Virus B	PCR	nasopharyngeal swab	Positive
Influenza Virus B	PCR	nasopharyngeal wash	Positive
Influenza Virus B	PCR	nasal wash	Positive
Influenza Virus B	PCR	other	Positive
Influenza Virus B	PCR	unknown or missing	Positive
Influenza Virus, not specified	PCR	nasopharyngeal swab	Positive
Influenza Virus, not specified	PCR	nasopharyngeal wash	Positive
Influenza Virus, not specified	PCR	nasal wash	Positive
Influenza Virus, not specified	PCR	other	Positive
Influenza Virus, not specified	PCR	unknown or missing	Positive

Appendix G. List of Polymerase Chain Reaction (PCR) Tests Used to Define Exclusion Criteria for this Request

Test Name	Test Category	Specimen Source	Test Result
Influenza			
Influenza Virus A	PCR	nasopharyngeal swab	Positive
Influenza Virus A	PCR	nasopharyngeal wash	Positive
Influenza Virus A	PCR	nasal wash	Positive
Influenza Virus A	PCR	other	Positive
Influenza Virus A	PCR	unknown or missing	Positive
Influenza Virus A and B	PCR	nasopharyngeal swab	Positive
Influenza Virus A and B	PCR	nasopharyngeal wash	Positive
Influenza Virus A and B	PCR	nasal wash	Positive
Influenza Virus A and B	PCR	other	Positive
Influenza Virus A and B	PCR	unknown or missing	Positive
Influenza Virus B	PCR	nasopharyngeal swab	Positive
Influenza Virus B	PCR	nasopharyngeal wash	Positive
Influenza Virus B	PCR	nasal wash	Positive
Influenza Virus B	PCR	other	Positive
Influenza Virus B	PCR	unknown or missing	Positive
Influenza Virus, not specified	PCR	nasopharyngeal swab	Positive
Influenza Virus, not specified	PCR	nasopharyngeal wash	Positive
Influenza Virus, not specified	PCR	nasal wash	Positive
Influenza Virus, not specified	PCR	other	Positive
Influenza Virus, not specified	PCR	unknown or missing	Positive